This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > Aplastic and Other Anemias > Efficacy > Diamond-Blackfan Anemia
Print

In this section:

Aplastic Anemia Diamond-Blackfan Anemia Other Rare Anemias
EU SmPC
Diamond Blackfan Anemia

EXJADE Decreases Serum Ferritin Levels in Patients With Diamond-Blackfan Anemia

In 2007, a 1-year prospective phase II study showed that EXJADE reduced levels of serum ferritin in patients with Diamond-Blackfan anemia and other anemias at the 20 and 30 mg/kg/day doses.1

EXJADE Reduces Serum Ferritin Levels in Patients
With Diamond-Blackfan and Other Rare Anemias
Reduction From Baseline in Serum Ferritin Levels in Patients with Diamond-Blackfan and Other Rare Anemias Chart


Learn more about
EXJADE dosing.


SAFETY PROFILE
ACROSS ANEMIAS


Learn more

In addition, a 1-year multicenter study reported in 2005 that EXJADE decreased serum ferritin levels in Diamond-Blackfan anemia patients (N=30) with iron toxicity.2

EXJADE has shown efficacy in reducing liver iron concentration levels in Diamond-Blackfan anemia patients

In 2007, a 1-year study in patients across a range of anemias (N=184) showed that EXJADE reduced liver iron concentration in patients with Diamond-Blackfan anemia.1

EXJADE Reduces Liver Iron Concentration in Patients
With Diamond-Blackfan Anemias (including aplastic anemia)3
EXJADE: LIC in Patients with Diamond-Blackfan anemias
More Information
Aplastic Anemia Diamond-Blackfan Anemia Other Rare Anemias
EU SmPC

References

  1. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.
  2. Tchernia G, E. Vichinsky E, Jeng M, et al. The once-daily oral iron chelator ICL670 is well tolerated and effective in treating transfusional iron overload in Diamond-Blackfan anemia patients. Abstract 0475. [The European Haemtological Society 10th Annual Meeting]. Haematologica. 2005;90(suppl 2): Abstract 0475.
  3. Data on file. Novartis Pharma AG, Basel, Switzerland.
TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:

  • in patients with beta thalassemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years
  • in patients with beta thalassemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older
  • in patients with other anemias aged 2 years and older
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed
Mean Liver Iron Concentration Reduction from Baseline with Diamond-Blackfan Anemia Chart Diamond-Blackfan Anemia Patients Mean Liver Iron Concentration Reduction from Baseline with Diamond-Blackfan Anemia Chart Diamond-Blackfan Anemia Patients